Jeffrey Wasserstein

DMDConnects Services, Inc. engages in enabling pharmaceutical, healthcare organizations, pharmaceutical marketing companies, and digital advertising agencies to reach, message, connect, and interact with physicians and healthcare professionals via multiple access channels. It also provides services such as targeted impressions and interactions through permission-based email, targeted on-line ad-serving, and mobile app advertising channels. The company was founded by Mark Benthin and Denis Martineau on April 1, 2005 and is headquartered in Longueuil, Canada.

Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™.

Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ.

Part of Merck & Co., Inc., Schering Canada, Inc. is a Canadian pharmaceutical company that manufactures and wholesales pharmaceutical products. The company is based in Pointe-Claire, Canada.

Fougera Pharmaceuticals, Inc. develops and manufactures specialty pharmaceuticals in dermatology. It operates through two core divisions: PharmaDerm and Fougera. The PharmaDerm division offers in-house expertise and facilities for formulation development, clinical development, manufacturing, distribution, and sales and marketing. The company was founded in 1849 and is headquartered in Melville, NY.

Dr. Reddy's Laboratories, Inc. develops pharmaceutical products. It also provides research and development activities and other medical testing services. The company is headquartered in Charlotte, NC.

Wachtell, Lipton, Rosen & Katz provides advisory and legal services. It specializes in mergers and acquisitions, strategic investments, takeovers and takeover defense, corporate and securities law, and corporate governance. The company was founded in 1965 and is headquartered in New York, NY.

Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It manufactures and markets branded and generic products including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The company was founded in 1971 and is headquartered in Lake Forest, IL.